Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem

Abstract excerpt

Chemotherapy-induced thrombocytopenia (CIT) is common, resulting in increased bleeding risk and chemotherapy delays, dose reduction, and treatment discontinuation, which can negatively affect oncologic outcomes. The only agent approved by the US Food and Drug Administration to manage CIT (oprelvekin) was voluntarily withdrawn from the market by the manufacturer, leaving few options for patients. Therefore,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood properties and coagulation
• Share to Lipid metabolism and disorders
• Share to Platelet Disorders and Treatments